APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neuroendocrine Carcinoma Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Neuroendocrine Carcinoma Drugs Market Outlook and Growth Opportunities 2026

21 December 2025192 pages

Choose your research edition.

Industry ResearchNeuroendocrine Carcinoma Drugs Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Neuroendocrine Carcinoma Drugs Industry Growth and Trends Forecast to 203297 pages · $3,450 USDMarket StructureGlobal Neuroendocrine Carcinoma Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neuroendocrine Carcinoma Drugs Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Neuroendocrine Carcinoma Drugs Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Neuroendocrine Carcinoma Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Neuroendocrine Carcinoma Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Neuroendocrine Carcinoma Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neuroendocrine Carcinoma Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Neuroendocrine Carcinoma Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Neuroendocrine Carcinoma Drugs market include Novartis AG, Roche, Xiaflex, Molecular Insight pharmaceuticals and Callisto Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Neuroendocrine Carcinoma Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Neuroendocrine Carcinoma Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Neuroendocrine Carcinoma Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Neuroendocrine Carcinoma Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Neuroendocrine Carcinoma Drugs Segment by Company

Novartis AG

Roche

Xiaflex

Molecular Insight pharmaceuticals

Callisto Pharmaceuticals

Neuroendocrine Carcinoma Drugs Segment by Type

Targeted Therapy

Somatostatin Analogs

Chemotherapy

Neuroendocrine Carcinoma Drugs Segment by Application

Oncology Centres

Clinics

Hospital

Ambulatory Surgery Centres

Neuroendocrine Carcinoma Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Neuroendocrine Carcinoma Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Neuroendocrine Carcinoma Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Neuroendocrine Carcinoma Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Neuroendocrine Carcinoma Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuroendocrine Carcinoma Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neuroendocrine Carcinoma Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuroendocrine Carcinoma Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Neuroendocrine Carcinoma Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neuroendocrine Carcinoma Drugs industry.

Chapter 3: Detailed analysis of Neuroendocrine Carcinoma Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Neuroendocrine Carcinoma Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Neuroendocrine Carcinoma Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Neuroendocrine Carcinoma Drugs Industry Trends Table 2. Neuroendocrine Carcinoma Drugs Industry Drivers Table 3. Neuroendocrine Carcinoma Drugs Industry Opportunities and Challenges Table 4. Neuroendocrine Carcinoma Drugs Industry Restraints Table 5. Global Neuroendocrine Carcinoma Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Neuroendocrine Carcinoma Drugs Revenue Share by Company (2021-2026) Table 7. Global Neuroendocrine Carcinoma Drugs Sales Volume by Company (k tons) & (2021-2026) Table 8. Global Neuroendocrine Carcinoma Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Neuroendocrine Carcinoma Drugs Average Price (US$/ton) of Company (2021-2026) Table 10. Global Neuroendocrine Carcinoma Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Neuroendocrine Carcinoma Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Neuroendocrine Carcinoma Drugs Company, Product Type & Application Table 13. Global Neuroendocrine Carcinoma Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Neuroendocrine Carcinoma Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Targeted Therapy Table 18. Significant Companies of Somatostatin Analogs Table 19. Significant Companies of Chemotherapy Table 20. Global Neuroendocrine Carcinoma Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (k tons) Table 21. Global Neuroendocrine Carcinoma Drugs Sales Volume by Type (2021-2026) & (k tons) Table 22. Global Neuroendocrine Carcinoma Drugs Sales Volume by Type (2027-2032) & (k tons) Table 23. Global Neuroendocrine Carcinoma Drugs Sales Volume Share by Type (2021-2026) Table 24. Global Neuroendocrine Carcinoma Drugs Sales Volume Share by Type (2027-2032) Table 25. Global Neuroendocrine Carcinoma Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Neuroendocrine Carcinoma Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Neuroendocrine Carcinoma Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Neuroendocrine Carcinoma Drugs Sales Value Share by Type (2021-2026) Table 29. Global Neuroendocrine Carcinoma Drugs Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Oncology Centres Table 31. Significant Companies of Clinics Table 32. Significant Companies of Hospital Table 33. Significant Companies of Ambulatory Surgery Centres Table 34. Global Neuroendocrine Carcinoma Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (k tons) Table 35. Global Neuroendocrine Carcinoma Drugs Sales Volume by Application (2021-2026) & (k tons) Table 36. Global Neuroendocrine Carcinoma Drugs Sales Volume by Application (2027-2032) & (k tons) Table 37. Global Neuroendocrine Carcinoma Drugs Sales Volume Share by Application (2021-2026) Table 38. Global Neuroendocrine Carcinoma Drugs Sales Volume Share by Application (2027-2032) Table 39. Global Neuroendocrine Carcinoma Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Neuroendocrine Carcinoma Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Neuroendocrine Carcinoma Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Neuroendocrine Carcinoma Drugs Sales Value Share by Application (2021-2026) Table 43. Global Neuroendocrine Carcinoma Drugs Sales Value Share by Application (2027-2032) Table 44. Global Neuroendocrine Carcinoma Drugs Sales by Region: 2021 VS 2025 VS 2032 (k tons) Table 45. Global Neuroendocrine Carcinoma Drugs Sales by Region (2021-2026) & (k tons) Table 46. Global Neuroendocrine Carcinoma Drugs Sales Market Share by Region (2021-2026) Table 47. Global Neuroendocrine Carcinoma Drugs Sales by Region (2027-2032) & (k tons) Table 48. Global Neuroendocrine Carcinoma Drugs Sales Market Share by Region (2027-2032) Table 49. Global Neuroendocrine Carcinoma Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Neuroendocrine Carcinoma Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Neuroendocrine Carcinoma Drugs Sales Value Share by Region (2021-2026) Table 52. Global Neuroendocrine Carcinoma Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Neuroendocrine Carcinoma Drugs Sales Value Share by Region (2027-2032) Table 54. Global Neuroendocrine Carcinoma Drugs Market Average Price (US$/ton) by Region (2021-2026) Table 55. Global Neuroendocrine Carcinoma Drugs Market Average Price (US$/ton) by Region (2027-2032) Table 56. Global Neuroendocrine Carcinoma Drugs Sales by Country: 2021 VS 2025 VS 2032 (k tons) Table 57. Global Neuroendocrine Carcinoma Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Neuroendocrine Carcinoma Drugs Sales by Country (2021-2026) & (k tons) Table 59. Global Neuroendocrine Carcinoma Drugs Sales Market Share by Country (2021-2026) Table 60. Global Neuroendocrine Carcinoma Drugs Sales by Country (2027-2032) & (k tons) Table 61. Global Neuroendocrine Carcinoma Drugs Sales Market Share by Country (2027-2032) Table 62. Global Neuroendocrine Carcinoma Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Neuroendocrine Carcinoma Drugs Sales Value Market Share by Country (2021-2026) Table 64. Global Neuroendocrine Carcinoma Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Neuroendocrine Carcinoma Drugs Sales Value Market Share by Country (2027-2032) Table 66. Novartis AG Company Information Table 67. Novartis AG Business Overview Table 68. Novartis AG Neuroendocrine Carcinoma Drugs Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 69. Novartis AG Neuroendocrine Carcinoma Drugs Product Portfolio Table 70. Novartis AG Recent Development Table 71. Roche Company Information Table 72. Roche Business Overview Table 73. Roche Neuroendocrine Carcinoma Drugs Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 74. Roche Neuroendocrine Carcinoma Drugs Product Portfolio Table 75. Roche Recent Development Table 76. Xiaflex Company Information Table 77. Xiaflex Business Overview Table 78. Xiaflex Neuroendocrine Carcinoma Drugs Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 79. Xiaflex Neuroendocrine Carcinoma Drugs Product Portfolio Table 80. Xiaflex Recent Development Table 81. Molecular Insight pharmaceuticals Company Information Table 82. Molecular Insight pharmaceuticals Business Overview Table 83. Molecular Insight pharmaceuticals Neuroendocrine Carcinoma Drugs Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 84. Molecular Insight pharmaceuticals Neuroendocrine Carcinoma Drugs Product Portfolio Table 85. Molecular Insight pharmaceuticals Recent Development Table 86. Callisto Pharmaceuticals Company Information Table 87. Callisto Pharmaceuticals Business Overview Table 88. Callisto Pharmaceuticals Neuroendocrine Carcinoma Drugs Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 89. Callisto Pharmaceuticals Neuroendocrine Carcinoma Drugs Product Portfolio Table 90. Callisto Pharmaceuticals Recent Development Table 91. Key Raw Materials Table 92. Raw Materials Key Suppliers Table 93. Neuroendocrine Carcinoma Drugs Distributors List Table 94. Neuroendocrine Carcinoma Drugs Customers List Table 95. Research Programs/Design for This Report Table 96. Authors List of This Report Table 97. Secondary Sources Table 98. Primary Sources List of Figures Figure 1. Neuroendocrine Carcinoma Drugs Product Image Figure 2. Global Neuroendocrine Carcinoma Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neuroendocrine Carcinoma Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Neuroendocrine Carcinoma Drugs Sales (2021-2032) & (k tons) Figure 5. Global Neuroendocrine Carcinoma Drugs Sales Average Price (US$/ton) & (2021-2032) Figure 6. Global Neuroendocrine Carcinoma Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Targeted Therapy Image Figure 10. Somatostatin Analogs Image Figure 11. Chemotherapy Image Figure 12. Global Neuroendocrine Carcinoma Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (k tons) Figure 13. Global Neuroendocrine Carcinoma Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Neuroendocrine Carcinoma Drugs Sales Volume Share by Type (2021-2032) Figure 15. Global Neuroendocrine Carcinoma Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Neuroendocrine Carcinoma Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Neuroendocrine Carcinoma Drugs Sales Value Share by Type (2021-2032) Figure 18. Oncology Centres Image Figure 19. Clinics Image Figure 20. Hospital Image Figure 21. Ambulatory Surgery Centres Image Figure 22. Global Neuroendocrine Carcinoma Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (k tons) Figure 23. Global Neuroendocrine Carcinoma Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Neuroendocrine Carcinoma Drugs Sales Volume Share by Application (2021-2032) Figure 25. Global Neuroendocrine Carcinoma Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Neuroendocrine Carcinoma Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Neuroendocrine Carcinoma Drugs Sales Value Share by Application (2021-2032) Figure 28. Global Neuroendocrine Carcinoma Drugs Sales by Region: 2021 VS 2025 VS 2032 (k tons) Figure 29. Global Neuroendocrine Carcinoma Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Neuroendocrine Carcinoma Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Neuroendocrine Carcinoma Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Neuroendocrine Carcinoma Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. North America Neuroendocrine Carcinoma Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Neuroendocrine Carcinoma Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Neuroendocrine Carcinoma Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Neuroendocrine Carcinoma Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Neuroendocrine Carcinoma Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Neuroendocrine Carcinoma Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. South America Neuroendocrine Carcinoma Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Neuroendocrine Carcinoma Drugs Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Neuroendocrine Carcinoma Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Neuroendocrine Carcinoma Drugs Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Neuroendocrine Carcinoma Drugs Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Targeted Therapy
  • Somatostatin Analogs
  • Chemotherapy
Applications
  • Oncology Centres
  • Clinics
  • Hospital
  • Ambulatory Surgery Centres
Companies covered
  • Novartis AG
  • Roche
  • Xiaflex
  • Molecular Insight pharmaceuticals
  • Callisto Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Neuroendocrine Carcinoma Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Neuroendocrine Carcinoma Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Neuroendocrine Carcinoma Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Neuroendocrine Carcinoma Drugs Market Dynamics
  1. 2.1 Neuroendocrine Carcinoma Drugs Industry Trends
  2. 2.2 Neuroendocrine Carcinoma Drugs Industry Drivers
  3. 2.3 Neuroendocrine Carcinoma Drugs Industry Opportunities and Challenges
  4. 2.4 Neuroendocrine Carcinoma Drugs Industry Restraints
3 Neuroendocrine Carcinoma Drugs Market by Company
  1. 3.1 Global Neuroendocrine Carcinoma Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Neuroendocrine Carcinoma Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Neuroendocrine Carcinoma Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Neuroendocrine Carcinoma Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Neuroendocrine Carcinoma Drugs Company Ranking (2024-2026)
  6. 3.6 Global Neuroendocrine Carcinoma Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Neuroendocrine Carcinoma Drugs Company Product Type and Application
  8. 3.8 Global Neuroendocrine Carcinoma Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Neuroendocrine Carcinoma Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Neuroendocrine Carcinoma Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Neuroendocrine Carcinoma Drugs Market by Type
  1. 4.1 Neuroendocrine Carcinoma Drugs Type Introduction
  2. 4.1.1 Targeted Therapy
  3. 4.1.2 Somatostatin Analogs
  4. 4.1.3 Chemotherapy
  5. 4.2 Global Neuroendocrine Carcinoma Drugs Sales Volume by Type
  6. 4.2.1 Global Neuroendocrine Carcinoma Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Neuroendocrine Carcinoma Drugs Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Neuroendocrine Carcinoma Drugs Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Neuroendocrine Carcinoma Drugs Sales Value by Type
  10. 4.3.1 Global Neuroendocrine Carcinoma Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Neuroendocrine Carcinoma Drugs Sales Value by Type (2021-2032)
  12. 4.3.3 Global Neuroendocrine Carcinoma Drugs Sales Value Share by Type (2021-2032)
5 Neuroendocrine Carcinoma Drugs Market by Application
  1. 5.1 Neuroendocrine Carcinoma Drugs Application Introduction
  2. 5.1.1 Oncology Centres
  3. 5.1.2 Clinics
  4. 5.1.3 Hospital
  5. 5.1.4 Ambulatory Surgery Centres
  6. 5.2 Global Neuroendocrine Carcinoma Drugs Sales Volume by Application
  7. 5.2.1 Global Neuroendocrine Carcinoma Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Neuroendocrine Carcinoma Drugs Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Neuroendocrine Carcinoma Drugs Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Neuroendocrine Carcinoma Drugs Sales Value by Application
  11. 5.3.1 Global Neuroendocrine Carcinoma Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Neuroendocrine Carcinoma Drugs Sales Value by Application (2021-2032)
  13. 5.3.3 Global Neuroendocrine Carcinoma Drugs Sales Value Share by Application (2021-2032)
6 Neuroendocrine Carcinoma Drugs Regional Sales and Value Analysis
  1. 6.1 Global Neuroendocrine Carcinoma Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Neuroendocrine Carcinoma Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Neuroendocrine Carcinoma Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Neuroendocrine Carcinoma Drugs Sales by Region (2027-2032)
  5. 6.3 Global Neuroendocrine Carcinoma Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Neuroendocrine Carcinoma Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Neuroendocrine Carcinoma Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Neuroendocrine Carcinoma Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Neuroendocrine Carcinoma Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Neuroendocrine Carcinoma Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Neuroendocrine Carcinoma Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Neuroendocrine Carcinoma Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Neuroendocrine Carcinoma Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Neuroendocrine Carcinoma Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Neuroendocrine Carcinoma Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Neuroendocrine Carcinoma Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Neuroendocrine Carcinoma Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Neuroendocrine Carcinoma Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Neuroendocrine Carcinoma Drugs Sales Value Share by Country, 2025 VS 2032
7 Neuroendocrine Carcinoma Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Neuroendocrine Carcinoma Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Neuroendocrine Carcinoma Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Neuroendocrine Carcinoma Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Neuroendocrine Carcinoma Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Neuroendocrine Carcinoma Drugs Sales by Country (2027-2032)
  6. 7.4 Global Neuroendocrine Carcinoma Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Neuroendocrine Carcinoma Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Neuroendocrine Carcinoma Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Neuroendocrine Carcinoma Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Neuroendocrine Carcinoma Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Neuroendocrine Carcinoma Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis AG
  2. 8.1.1 Novartis AG Company Information
  3. 8.1.2 Novartis AG Business Overview
  4. 8.1.3 Novartis AG Neuroendocrine Carcinoma Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Novartis AG Neuroendocrine Carcinoma Drugs Product Portfolio
  6. 8.1.5 Novartis AG Recent Developments
  7. 8.2 Roche
  8. 8.2.1 Roche Company Information
  9. 8.2.2 Roche Business Overview
  10. 8.2.3 Roche Neuroendocrine Carcinoma Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Roche Neuroendocrine Carcinoma Drugs Product Portfolio
  12. 8.2.5 Roche Recent Developments
  13. 8.3 Xiaflex
  14. 8.3.1 Xiaflex Company Information
  15. 8.3.2 Xiaflex Business Overview
  16. 8.3.3 Xiaflex Neuroendocrine Carcinoma Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Xiaflex Neuroendocrine Carcinoma Drugs Product Portfolio
  18. 8.3.5 Xiaflex Recent Developments
  19. 8.4 Molecular Insight pharmaceuticals
  20. 8.4.1 Molecular Insight pharmaceuticals Company Information
  21. 8.4.2 Molecular Insight pharmaceuticals Business Overview
  22. 8.4.3 Molecular Insight pharmaceuticals Neuroendocrine Carcinoma Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Molecular Insight pharmaceuticals Neuroendocrine Carcinoma Drugs Product Portfolio
  24. 8.4.5 Molecular Insight pharmaceuticals Recent Developments
  25. 8.5 Callisto Pharmaceuticals
  26. 8.5.1 Callisto Pharmaceuticals Company Information
  27. 8.5.2 Callisto Pharmaceuticals Business Overview
  28. 8.5.3 Callisto Pharmaceuticals Neuroendocrine Carcinoma Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Callisto Pharmaceuticals Neuroendocrine Carcinoma Drugs Product Portfolio
  30. 8.5.5 Callisto Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Neuroendocrine Carcinoma Drugs Value Chain Analysis
  2. 9.1.1 Neuroendocrine Carcinoma Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Neuroendocrine Carcinoma Drugs Sales Mode & Process
  6. 9.2 Neuroendocrine Carcinoma Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Neuroendocrine Carcinoma Drugs Distributors
  9. 9.2.3 Neuroendocrine Carcinoma Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst